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Available online 12 October 2014Abstract The purpose of this study was to evaluate the therapeutic potential of human induced pluripotent stem (iPS) cell-derived
macrophage-like cells for Alzheimer's disease (AD). In previous studies, we established the technology to generate macrophage-like
myeloid lineage cells with proliferating capacity from human iPS cells, and we designated the cells iPS-ML. iPS-ML reduced the level
of Aβ added into the culturemedium, and the culture supernatant of iPS-ML alleviated the neurotoxicity of Aβ. We generated iPS-ML
expressing the Fc-receptor-fused form of a single chain antibody specific to Aβ. In addition, we made iPS-ML expressing Neprilysin-2
(NEP2), which is a protease with Aβ-degrading activity. In vitro, expression of NEP2 but not anti-Aβ scFv enhanced the effect to
reduce the level of soluble Aβ oligomer in the culture medium and to alleviate the neurotoxicity of Aβ. To analyze the effect of
iPS-ML expressing NEP2 (iPS-ML/NEP2) in vivo, we intracerebrally administered the iPS-ML/NEP2 to 5XFAD mice, which is a mouse
model of AD. We observed significant reduction in the level of Aβ in the brain interstitial fluid following administration of iPS-ML/
NEP2. These results suggested that iPS-ML/NEP2 may be a potential therapeutic agent in the treatment of AD.
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443Aβ degradation iPS-ML expressing NEP2Introduction proteolytic enzyme neprilysin and reduced the Aβ burden inAlzheimer's disease (AD) is the most common cause of
neurodegenerative dementia in elderly people; currently,
the disease affects more than 36 million people worldwide.
AD is characterized by slowly progressive recent memory
deficits, cognitive impairment, and personality changes
associated with neuronal loss (Blennow et al., 2006). The
main risk factor of sporadic AD is aging; prevalence after
65 years of age is 5%, increasing to about 30% of people aged
over 85 years old. As a result of the prolonged lifespans in
our aging society, the number of patients is expected to
continue to increase in the future (Ferri et al., 2005). At the
moment, only symptomatic therapies for this disease are
available, and the development of a disease-modifying
therapy is a required (Carter et al., 2010).
The two major pathological hallmarks of AD are extracellu-
lar senile plaques and intraneuronal neurofibrillary tangles.
Senile plaques mainly consist of β amyloid peptide (Aβ),
especially the Aβ1–42 isoform. Based on the genetic findings
from familial AD studies, Aβ is assumed to be the primary
inducer of AD pathology (Hardy and Selkoe, 2002; Tanzi and
Bertram, 2005). Transgenic mouse lines that accumulate Aβ in
their brains are used as experimental models to identify a
therapeutic approach for AD. Previous studies have shown that
vaccination reduced the brain Aβ deposits and improved
cognitive functions in these model animals (Janus et al., 2000;
Morgan et al., 2000; Schenk et al., 1999). Nevertheless, in the
human clinical trials, vaccination therapy has failed to improve
cognitive function so far (Robinson et al., 2004). Furthermore,
several adverse events such as meningo-encephalitis (Nicoll et
al., 2003), vasogenic edema (Salloway et al., 2009), and micro
hemorrhage (Boche et al., 2008) occurred in some of the
treated patients.
Inflammatory changes are observed in AD brains, particu-
larly at the vicinity of senile plaques. They are abundant in
activatedmicroglia, which are the resident macrophages in the
central nervous system, in both human AD samples (Mattiace et
al., 1990; Perlmutter et al., 1990) and transgenic mouse
models (Frautschy et al., 1998). Aβ-activatedmicroglia release
a wide variety of neurotoxic molecules including proinflamma-
tory cytokines (Griffin, 2006), reactive oxygen species (Reddy
et al., 2009), and complement proteins (Bonifati and Kishore,
2007), which contribute to the neurodegeneration in AD. On
the other hand, microglia have beneficial effects against AD as
a result of neurotrophic agent secretion and clearing Aβ by
phagocytosis (Mizuno et al., 2004; Yan et al., 2006). In
addition, in vitro experiments strongly suggest a role for
microglia in phagocytic clearance of Aβ. Phagocytosis of Aβ by
exogenously administeredmicroglia was indicated by an in vivo
study using intra-hippocampal Aβ-injected rats (Takata et al.,
2007). However, their exact role in the pathogenesis of AD
remains to be elucidated.
Macrophages are innate immune cells with the capacity
to eliminate invading pathogens and dying cells, and
maintain homeostasis in many tissues. Manipulation of
macrophages to enhance their capacity to efficiently clear
Aβ with low neurotoxicity is expected to provide therapeutic
treatments for AD (Malm et al., 2010). A recent study
demonstrated that peripherally transplanted CD11b+ bone
marrow-derived monocytes (BMM) migrate into the vicinity
of Aβ plaques, and that these modified cells secreted themodel mice (Lebson et al., 2010).
These results suggest the potential of bone marrow-
derived myeloid-lineage cells in alleviating AD pathology and
as therapeutic agents. However, to use myeloid-lineage cells
in AD therapy, an adequate supply of therapeutic cells is
necessary. Preparation of a large quantity of myeloid lineage
cells from bone marrow or peripheral blood of AD patients
for the treatment is not practical and the limited cellular
sources obstruct the development of a cell-based therapy.
Recently, we have developed an iPS cell-based method to
generate abundant quantities of myeloid lineage cells. Using
this technology, it may be possible to resolve the issue of
limited cell sources (Senju et al., 2009). Previously, we have
reported the generation of iPS cell-derived macrophage-like
myeloid lineage cells (iPS-MC) that were genetically modi-
fied to express a membrane-bound form of single chain
antibody (scFv) specific to Aβ. In the in vitro analysis, the
Aβ-specific scFv-transfectant iPS-MC exhibited efficient
Aβ-specific phagocytic activity (Senju et al., 2011).
Neprilysin is a membrane-bound protease with efficient Aβ
degradation activity (Iwata et al., 2001). The amino acid
sequence of membrane metallo-endopeptidase-like protein
(MMEL, neprilysin-2) has been reported to be highly homologous
with neprilysin. Neprilysin-2 (NEP2) has two alternatively
spliced forms: a membrane-bound and soluble-secreted vari-
ant. The soluble-secreted form is also known as soluble,
secreted endopeptidase (SEP) (Ikeda et al., 1999). In mice,
Nep2 is expressed in testis and involved in sperm function, as
well as modulating fertilization and early embryonic develop-
ment (Ghaddar et al., 2000). NEP2 has also been characterized
in the human brain, and a recent study reported that NEP2
activity is reduced in mild cognitive impaired patients and AD
patients (Huang et al., 2012). Also Hafez and colleagues have
demonstrated using gene knockout and transgenic animals
that NEP2 contributes to Aβ degradation in vivo (Hafez et al.,
2011).
In this study, we genetically modified macrophage-like
myeloid lineage cells with proliferating capacity generated
from human iPS cells (iPS-ML) (Haruta et al., 2013; Koba et
al., 2013) to express the Aβ-degrading protease NEP2. In
vitro, the transfected macrophages secreted NEP2 and
reduced the levels of Aβ1–42 oligomers in the culture
medium. In addition, they protected co-cultured SH-SY5Y
neuroblastoma cells from the toxicity of Aβ1–42 oligomers.
To evaluate the potential for AD therapy, we examined
whether iPS-ML could lower the levels of Aβ1–42 peptide in
brain interstitial fluid (ISF) in AD model mice. To this end,
we set up a microdialysis-based ISF sampling system to
examine the level of soluble Aβ1–42 peptide in the mouse
brain ISF. Administration of NEP2-secreting iPS-ML into the
hippocampus of the AD model transgenic mice diminished
Aβ1–42 in the ISF, thereby suggesting the possibility of
NEP2-secreting iPS-ML as a therapeutic means for AD.Materials and methods
Cells and antibodies
All experiments using human sampleswere conducted with the
approval of the Institutional Review Board of Kumamoto
444 K. Takamatsu et al.University. Human iPS cells were previously established by
lentivirus-mediated introduction of reprogramming factors
into fibroblasts and maintained as previously described
(Senju et al., 2011). The following mAbs conjugated with
fluorescein isothiocyanate (FITC) or phycoerythrin (PE) were
purchased from BD Pharmingen (San Diego, CA), Beckman
Coulter (Brea, CA), Miltenyi Biotec (Bergish-Gladbach, Germa-
ny), Sigma-Aldrich (St. Louis, MO), or eBioscience (San Diego,
CA): anti-CD45 (clone HI30, mouse IgG1), anti-CD33 (WM53,
mouse IgG1), anti-CD36 (FA6.152, mouse IgG1), anti-CD11b
(ICRF44, mouse IgG1), anti-CD13 (WM15, mouse IgG1),
anti-CD87 (62022, mouse IgG1). For isotype-matched controls,
mouse IgG1 (MOPC-21) was used.
Plasmid construction and generation of
recombinant lentivirus
A cDNA fragment of human cMYC was obtained by PCR and
cloned into the pENTR-TOPO vector (Invitrogen, Carlsbad, CA,
USA). cDNAs of human EZH2, NEP-2, BMI1, and MDM2 were
provided by RIKEN BioResource Center (Tsukuba, Japan) or
NRBC (Tokyo, Japan). The Aβ-specific scFv construct was
reported previously (Senju et al., 2011). The cDNA fragments
were transferred to a lentiviral expression vector, pCSII-EF
(Miyoshi et al., 1998) or pCSII-EF/IRES-NEO, by using the LR
clonase system (Invitrogen). pCSII-EF and the plasmids for
lentiviral vector packaging, pCMV-VSV-G-RSV-Rev and pCAG-
HIVgp, were kindly provided by Dr H. Miyoshi (RIKEN
BioResource Center). Plasmid constructs were introduced
into 293T cells by using lipofection (Lipofectamine 2000,
Invitrogen), and recombinant lentivirus was recovered from
the culture supernatant by centrifugation (50,000 g, 2 h)
3 days later.
Generation of human iPS cell-derived proliferating
myeloid cells
Two lines of human iPS cells were used in this study; one
(iPSL) was established from skin fibroblasts by using lenti
virus-mediated introduction of reprogramming factors
(Senju et al., 2011) and the other (iPSS) was established
from peripheral blood T cells by using sendai virus-mediated
introduction of reprogramming factors (Cytotune, Dnavec,
Tsukuba, Japan). iPS cells were induced to differentiate into
myeloid cells (iPS-MC) according to a previously established
procedure (Senju et al., 2011). To establish iPS-ML (Haruta
et al., 2013; Koba et al., 2013), iPS-MC derived from iPSL
were introduced with expression vectors for cMYC plus EZH2
(iPS-ML-A) and iPS-MC derived from iPSS were introduced
with cMYC, BMI1, plus MDM2 (iPS-ML-B). Both iPS-ML were
cultured in the presence of M-CSF (50 ng/mL) and GM-CSF
(50 ng/mL). To generate NEP-2-transfectant, the iPS-ML
were infected with the recombinant lentivirus vector
including IRES-Neomycin-resistance cassette for NEP2 and
cultured in the presence of G-418 to select iPS-ML stably
expressing NEP2.
Flow cytometric analysis
The cell samples were treated with human Fc-receptor-
blocking reagent (Miltenyi Biotec) for 10 min, stained withthe fluorochrome-conjugated mAb for 30 min, and washed 3
times with phosphate-buffered saline/2% fetal calf serum.
The stained cell samples were analyzed using a FACScan flow
cytometer (BD Bioscience, Bedford, MA, USA). For detection
of cell surface NEP2, cells were incubated with polyclonal
goat anti-human NEP2 antibody (AF2340; R&D Systems) for
30 min at 4 °C and with anti-goat IgG FITC (secondary
antibody) for 30 min at 4 °C. For intracellular staining of
NEP2, iPS-ML were fixed and permeabilized using IntraPrep
reagent (Beckman Coulter), and stained with a polyclonal
NEP2 antibody as described above. Goat IgG was also used as
control. The cell samples were analyzed using a FACScan flow
cytometer.Western blot analysis
After the iPS-ML were cultured for 24 h, they were centrifuged
and separated into cell pellets and culture supernatants. The
cell pellets were subjected to protein extraction by using
CytoBuster™ Protein Extraction Reagent (Novagen, San Diego,
CA, USA). Protein concentration was determined using a BCA
protein assay kit (PIERCE, Rockford, IL, USA). After determina-
tion of protein concentration, sample buffer containing
2-mercaptoethanol was added to the culture supernatants
and cell-extracts. Samples of supernatants and cell-extracts
were subjected to SDS-PAGE on 4–20% TGX Protean® gels
(Bio-Rad, Hercules, CA, USA) by using a Mini Protean® II
Electrophoresis Cell (Bio-Rad), and electronically transferred
onto Immun-Blot® PVDF membranes (Bio-Rad) using a Mini
Trans-Blot® Cell (Bio-Rad) at 100 mA for 1 h. After blocking
overnight in Tris-buffered saline (0.1 M Tris–HCl, 0.9% NaCl,
pH 7.4) containing 0.1% Tween 20 and 5% skimmilk at 4 °C, the
blots were incubated with NEP2-specific polyclonal antibody
for 1 h and subsequently with an anti-goat horseradish
peroxidase (HRP)-conjugated secondary antibody for 1 h. As a
control for equal protein loading in the analysis of cell extracts,
membranes were also probed with a mouse anti-β-actin
antibody (Sigma–Aldrich) and exposed to an HRP-conjugated
anti-mouse antibody. Signals were visualized using ECL plus
(Amersham Pharmacia Biotech, Buckinghamshire, UK) reagents
and detected by a FPM100 developer (Fujifilm, Tokyo, Japan).
All procedures were performed at room temperature unless
otherwise stated.Preparation of Aβ oligomers
Soluble Aβ1–42 oligomer (AβO) solutions were prepared as
previously described (Stine et al., 2003). Briefly, synthetic
human Aβ1–42 (Peptide Institute, Osaka, Japan) was dissolved
at 1 mM in cold 100% 1,1,1,3,3,3-hexafluoro-2-propanol
(HFIP). The peptide was incubated at room temperature for
2 h to ensure it was monomeric and unstructured. The HFIP
was dried by the vacuum desiccator and the resulting peptide
film was stored at −20 °C until use. To form oligomers, the
film of Aβwas dissolved in DMSO at 5 mM and further diluted to
100 μM in phenol red-free F12medium (Ham's F-12, BioSource)
by vortexing for 10 min. Subsequently, the solution was aged
for 24 h at 4–8 °C. The sample was then centrifuged at
15,000 g for 10 min at 4–8 °C, and the soluble oligomers
remained in the supernatant.
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iPS-ML were cultured for 24 h and the culture supernatants
were collected. iPS-ML (1 × 105 /well in 96-well culture plates)
or collected supernatants were added with 10 μM of AβO in the
presence or absence of 10 μMphosphoramidon (Sigma-Aldrich).
After 24 h of incubation at 37 °C (5% CO2), the culture medium
was centrifuged to remove cell debris (1500 g, 10 min, 4 °C).
The amount of Aβ1–42 in the resultant supernatants was
quantified using an Aβ42-specific ELISA kit (Wako Chemicals,
Tokyo, Japan). Statistical analysis was performed using
two-tailed Student's t-tests and comparison with the control
(without iPS-ML).
Analysis of AβO cytotoxicity
SH-SY5Y neuroblastoma cells were plated at a density of
1 × 104 cells/well in 96-well plates in DMEM/F12 (1:1) medium
supplemented with 10% (v/v) fetal bovine serum (FBS),
100 U/mL penicillin and 100 μg/mL streptomycin, and incu-
bated for 24 h at 37 °C in 5% CO2. After incubation for 24 h,
the medium was replaced with serum-free DMEM/F12 (1:1)
medium containing the AβO solution. The cells were incubated
for 48 h and the number of live cells was analyzed using
the CellTiter 96 assay kit (Promega, Madison, WI) according
to the kit protocol. Briefly, 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2 H-tetrazolium,
inner salt (MTS) was added to culture plates and the plates
were incubated at 37 °C for 3 h. Absorbance at 490 nm was
measured to quantify the number of live cells. The results are
expressed as the percentage of MTS reduced relative to the
control samples, assuming the absorbance of the control cells
was 100%. To analyze the effect of iPS-ML on the death of
SH-SY5Y cells, culture supernatants were prepared from iPS-ML
cultured at a density of 2.5 × 105 cells/mL for 24 h. SH-SY5Y
cells were plated at a density of 1 × 104 cells perwell in 96-well
plates (n = 3 wells in each experimental condition). After 24 h,
the culture medium from the SH-SY5Y cells was replaced with
the culture supernatant from the iPS-ML and AβO and/or the
NEP-2 inhibitor phosphoramidon. After 48 h of incubation, the
number of live SH-SY5Y cells was quantified using the CellTiter
96 assay kit, as described above.
Generation of scid/5XFAD mice
5XFAD mice (Oakley et al., 2006) harbor three mutations in
the amyloid precursor protein (APP) gene and two in the
presenilin-1 (PS1) gene and were used for in vivo analysis.
These mice increase soluble Aβ production, develop senile
plaques by 4 to 5 weeks of age, and show neuronal damage
including intraneuronal accumulation of Aβ and cognitive
deficits by 5 months. 5XFAD mice were crossed to scid mice,
and hemizygous 5XFAD transgenic mice with scid/scid
genetic backgrounds were used in the experiments.
In vivo microdialysis and iPS-ML transplantation
To measure the levels of soluble Aβ1–42 in the hippocampus
ISF of awake, freely moving 5XFAD mice, microdialysis was
performed as previously described (Takeda et al., 2011) with
some modifications. Probe implantation was performed aspreviously described (Cirrito et al., 2003). Briefly, the
animals were anesthetized with sodium pentobarbital
(intraperitoneal injection, 50 mg/kg; Dainippon Sumitomo
Pharma, Osaka, Japan), while a guide cannula (8 mm length)
was stereotaxically implanted in the right hippocampus
(bregma 3.1 mm, 2.4 mm lateral to the midline, and 1.1 mm
ventral to dura at a 12° angle). The guide cannula was fixed
using an anchoring bone screw and binary dental cement.
More than 3 days after guide cannula implantation, the mice
were placed in a standard microdialysis cage and a probe
was inserted through the guide. The microdialysis probe had
an 8 mm shaft with a 4 mm, 1000 kDa molecular weight
cutoff polyethylene membrane (PEP-8-04, Eicom, Kyoto,
Japan). Before use, the probe was conditioned by brief
dipping in ethanol, and then washed with perfusion buffer
(0.15% bovine serum albumin in Ringer's solution) that was
filtered through a 0.22 μm pore size membrane (GL Sciences
Inc., Japan). The preconditioned probe's outlet and inlet
were connected to a peristaltic pump (Eicom) and
microsyringe pump (Eicom), respectively, using fluorinated
ethylene propylene (FEP) tubing (φ250 μm i.d.). After
insertion of the probe, to obtain a stable 2 h of baseline
recordings, the probe and connecting tubes were perfused
with the perfusion buffer for 180 min at a flow rate of
10 μL/min before the baseline sample collection. The flow
rate was maintained at 1.0 μL/min with a peristaltic pump
(Eicom) and microsyringe pump (Eicom).
Samples were stored at 4 °C for less than 24 h in a
polypropylene tube before being subjected to ELISA testing.
Samples were denatured with 500 mM guanidine HCl, which
solubilizes aggregated Aβ, and the Aβ1–42 levels were
measured using a sandwich ELISA kit (Wako Chemicals).
Baseline levels of ISF Aβ1–42 were defined as the mean
concentration of Aβ over the 2 h preceding IPS-ML trans-
plantation or Ringer's solution injection. For each animal, all
Aβ levels were normalized to the basal Aβ concentration.
For iPS-ML transplantation into the hippocampus, micro-
dialysis probes with a separate injection port at the tip
(PEP-8-04-MI, Eicom) were used. This permitted us to
perform microdialysis and still administer iPS-ML to the
hippocampus. IPS-ML were preloaded into a 10 μL Hamilton
syringe and connected to the infusion port of the microdi-
alysis probe with FEP tubing. The iPS-ML suspended
in Ringer's solution (5 × 107 /mL) were injected into the
hippocampus 3 μL for 3 min.Histological analysis
iPS-ML labeled with PKH26 (Sigma-Aldrich) or introduced
with GFP-expression vector were injected into the
hippocampus of mice as described above. For microscopic
examination, the brain tissue was removed, fixed in 4%
paraformaldehyde/phosphate-buffered saline, and embed-
ded in Tissue-TEK OCT compound (Sakura Finetechnical,
Tokyo, Japan). Frozen sections of 20-μm thickness were
made using a cryostat (MICROM HN505N; Thermo Scientific,
Kalamazoo, MI). The tissue sections were stained with Congo
red to detect amyloid plaques, or stained with DAPI and
analyzed using fluorescence microscopes (Axio Observer Z1,
Carl Zeiss, Oberkochen, Germany. and FV1200, Olympus,
Tokyo, Japan).
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Generation of iPS-ML expressing Neprilysin-2
We previously established a method to generate CD43+CD11b+
myeloid-lineage cells from human iPS cells, and designated
them iPS-MC (iPS cell-derived myeloid-lineage cells) (Senju et
al., 2011). iPS-MC proliferated in the presence of granulo-
cyte–macrophage colony-stimulating factor (GM-CSF) and
macrophage-colony-stimulating factor (M-CSF) for 7–14 days,
and then stopped proliferating. The generation of iPS-MC with
long-term proliferation would be a beneficial source of
large amounts of macrophages for cell-based therapies. We
had found that simultaneous introduction of cMYC in combi-
nation with EZH2, BMI1, or MDM2 resulted in the prolonged
proliferation of iPS-MC. The cells continuously propagated for
more than 3 months in the presence of M-CSF, with a doubling
time of 24–36 h. Based on the observation, we established a
method to generate a large quantity of humanmyeloid lineage
cells. We named the iPS cell-derived long-term proliferating
myeloid cells iPS-ML (iPS cell-derived myeloid cell line)
(Haruta et al., 2013; Koba et al., 2013). Morphology and
hematopoietic and myeloid markers, such as CD45, CD36,
CD11b, CD13, CD87, and CD33 of iPS-ML generated by
introduction of cMYC plus EZH2 (iPS-ML-A) and those generat-
ed by introduction of cMYC, BMI1, plus MDM2 (iPS-ML-B) into
iPS-MC are shown in Fig. 1. A growth curve and results of
chromosomal analysis of iPS-ML-B are shown in Supplemental
Fig. 1.
iPS-ML with Aβ-degrading activity could be useful for
therapy of AD. We generated an iPS-ML expressing a protease
with Aβ-degrading activity. Neprilysin (NEP) is a well-known
Aβ-degrading zinc-dependent metalloprotease (Iwata et al.,
2001). NEP is a membrane-bound protease, and we considered
that, rather than using a membrane-bound protease, a
secreted type of the protease would be more appropriate
and effective to degrade extracellular Aβ oligomers (AβO).
Membrane metallo-endopeptidase-like protein (MMEL, NEP2),
expressed as both membrane-bound protein and secereted
protein, has also Aβ-degrading activity (Hafez et al., 2011).
To generate NEP2-expressing iPS-ML, we introduced
a NEP2-expression vector into the iPS-ML-A by lentivirus-
mediated transduction. Flow cytometric analysis of the
NEP2-transfectant iPS-ML-A (iPS-ML-A/NEP2) detected NEP2
both on the cell surface and within the cells (Fig. 2A). Western
blot analysis detected the NEP2 protein in both the cell lysate
and the culture supernatant of the IPS-ML-A/NEP2 (Fig. 2B).
These results indicate that the iPS-ML-A/NEP2 expressed NEP2
on the cell surface and also secreted NEP2 into the culture
medium.
NEP-2-expressing iPS-ML and culture supernatants
degrade Aβ42 oligomers
To examine the ability of iPS-ML to reduce AβO,we added AβO
to the culture of non-transfected iPS-ML-A, anti-Aβ-scFv
(Senju et al., 2011)-transfected iPS-ML-A (iPS-ML-A/scFvAβ),
and iPS-ML-A/NEP2. After 24 h of incubation, the culture
supernatant was collected and AβO in the supernatant was
quantified by ELISA. In Fig. 3A, data are presented as the
percentage of AβO remaining compared to a control condition(without iPS-ML). The results indicate that even non-
transfected iPS-ML-A had a reducing effect on the level of
AβO in the culture medium by about 30%. The effect of
iPS-ML-A/scFvAβ was similar to that of the non-transfected
iPS-ML-A, thereby indicating that expression of anti-Aβ-scFv
did not enhance the AβO-reducing effect. In contrast,
the iPS-ML-A/NEP2 showed a much more potent effect to
reduce AβO (about 90% reduction) as compared with the
non-transfected iPS-ML-A. The enhanced AβO-reducing activ-
ity gained by the expression of NEP2 was almost totally
canceled by the presence of phosphoramidon, which is a
protease inhibitor known to inhibit the activity of NEP2.
We also analyzed the AβO-reducing activity of the culture
supernatant of iPS-ML-A, iPS-ML-A/scFvAβ, and iPS-ML-A/
NEP2. As shown in Fig. 3B, the culture supernatant of the
iPS-ML-A and iPS-ML-A/scFvAβ did not reduce the level of
AβO, thereby suggesting that the reduction of AβO by the
non-transfected iPS-ML-A and iPS-ML-A/scFv Aβ (Fig. 3A)
was mediated by the endocytosis of AβO by iPS-ML-A or by
effect of some membrane-associated proteases other than
NEP2. The culture supernatant of the iPS-ML-A/NEP2
reduced the level of AβO by about 50%, and the effect was
abolished by the presence of phosphoramidon.
Thus, both the iPS-ML-A/NEP2 and its culture supernatant
reduced the level of AβO. On the other hand, non-transfected
iPS-ML-A and iPS-ML-A/scFv Aβ, but not their culture super-
natants, reduced the level of AβO. A previous study reported
that only the NEP2β splice form of human NEP2, which is
located at the cell surface, degrades Aβ (Huang et al., 2008).
The results of our experiments demonstrated that the secreted
form of NEP2 also degrades AβO.
To confirm the reproducibility of the results described
above, we repeated the experiments using a different
iPS-ML (iPS-ML-B), which had been generated by introduc-
tion of cMYC, BMI1, plus MDM2 as proliferation factors. As
shown in Supplementary Fig. 2, iPS-ML-B also reduced the
level of AβO in the culture medium. NEP2-transfectant
iPS-ML-B (iPS-ML-B/NEP2) exhibited higher activity to re-
duce AβO in the culture medium than non-transfectant
iPS-ML-B (Supplementary Fig. 2).
Taken together, iPS-ML could reduce the level of AβO in
the culture supernatant, and the effect was enhanced by the
forced expression of NEP2. In addition, NEP2 secreted from
NEP2-transfectant iPS-ML also reduced AβO in the culture
supernatant.NEP2-expressing iPS-ML attenuates the neurotoxicity
induced by Aβ42 oligomers
Microglia could exacerbate the pathogenesis of AD by
accelerating neuronal loss and cognitive deficits through the
production of neurotoxic pro-inflammatory cytokines such as
interleukinh1 (IL-1), IL-6, and tumor necrosis factor-alpha
(TNF-α) (Griffin, 2006). Although reduction of AβO by iPS-ML
may inhibit disease progress, if it comes at the cost of
increased neurotoxicity, then it is doubtful whether treatment
with iPS-ML is beneficial for the AD patients.
We investigated whether culture supernatants of iPS-ML
exacerbate or alleviate the neurotoxic effect of AβO.
Toxicity of AβO on the SH-SY5Y neuroblastoma cell line
was assessed by a modified MTT reduction assay, utilizing a
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Figure 1 Morphology and cell surface molecules of iPS cell-derived myeloid cell line (iPS-ML). A. Phase contrast images of iPS
cell-derived myeloid cell line (iPS-ML-A and iPS-ML-B) in culture plate are shown. B. Expression of CD45, CD36, CD11b, CD13, CD87,
and CD33 on iPS-ML was analyzed by flow cytometry. Staining profiles of the specific monoclonal antibody (mAb; thick lines) and an
isotype-matched control mAb (gray area) are shown.
447Aβ degradation iPS-ML expressing NEP2tetrazolium compound (MTS). Incubation in the presence of
more than 5 μM AβO to SH-SY5Y cell cultures resulted in
significant cell death (Fig. 4A).
Culture supernatant of non-transfected iPS-ML-A reduced
the toxicity of AβO against SH-SY5Y cells (Fig. 4B). As shown
in Fig. 3B, culture supernatant of non-transfected iPS-ML-A
did not reduce the level of AβO. Therefore, the observed
inhibition of death in the SH-SY5Y cells was not mediated by
the reduction of AβO. Probably, iPS-ML produced some
soluble factors that protect the SH-SY5Y cells from death.
Culture supernatant of iPS-ML-A/NEP2 reduced the neuro-
toxicity more efficiently than that of non-transfected
iPS-ML-A (Fig. 4B). Addition of phosphoramidon to the
supernatant of iPS-ML-A/NEP2 abolished most of the effect
of NEP2-transgene. Culture supernatant of iPS-ML-B also
protected SH-SY5Y cells from toxic effect of AβO (Fig. 4C).
The neuroprotective effect of culture supernatant of
iPS-ML-B was also enhanced by forced expression of NEP2
(Fig. 4C).
Taken together, these results demonstrate that iPS-ML
produced some soluble neuroprotective factor that protected
SH-SY5Y cells from AβO-induced death. In addition, NEP2
secreted by NEP2-transfectant iPS-ML further reduced the
toxicity of AβO by decreasing the level of AβO.Intrahippocampally transplanted NEP-2-expressing
human iPS-MP reduces brain ISF Aβ in 5XFAD mice
We examined the effect of iPS-ML-A/NEP2 on AβO levels in
vivo. To this end, we used 5XFAD mice, which accumulate
Aβ in their brain tissue that is observable from 2 months
of age. We planned to intrahippocampally administrate
iPS-ML-A/NEP2 into 5XFAD mice and examine whether it
resulted in reduction of AβO in the brain tissue. To avoid the
immune-mediated rejection of transferred cells and ac-
companying inflammation, we crossed 5XFAD mice to
immune-compromised SCID mice and establish 5XFAD mice
with scid/scid genetic backgrounds (5XFAD/scid mice).
Continuous sampling of ISF by microdialysis was done
to assess the dynamic change of soluble Aβ in awake,
free-moving animals. To this end, we inserted the microdi-
alysis probe with a microinjection tube into the right
hippocampus of 3–4-month old 5XFAD/scid male mice. To
confirm proper administration of iPS-ML into the hippocam-
pus, we injected fluorescent dye (PKH26)-labeled iPS-ML-A
or GFP-expressing iPS-ML-B, and histologically analyzed the
hippocampus. Staining of the tissue sections with Congo red
visualized the amyloid plaques in the hippocampus (Fig. 5A).
Migration of iPS-ML into a region adjacent the microinjection
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Figure 2 Expression of NEP2 by NEP2-expressing iPS-ML. A. Flow cytometric analysis of the cell surface and intracellular expression
of NEP2 in NEP2-expressing iPS-ML (iPS-ML-A/NEP2). The staining profiles of the specific monoclonal antibodies (mAb; thick lines) and
an isotype-matched control mAb (gray area) are shown. B. Cell extracts and culture supernatants of non-transfected iPS-ML-A and
iPS-ML-A/NEP2 were subjected to western blot analysis to detect NEP2 protein. Recombinant human NEP2/MMEL was used as a
positive control. β-actin was also probed for equal loading of cell extracts.
448 K. Takamatsu et al.tube insertion site was revealed by fluorescence microscopy
(Figs. 5B and C).
After 2 h of baseline sampling, iPS-ML-A, iPS-ML-A/NEP2
or Ringer's solution as control were injected into the right
hippocampus via the microinjection tube. Basal levels of
brain ISF Aβ1–42 were defined as their mean concentration
over 2 h preceding iPS-ML administration. The effect of
iPS-ML transfer was assessed by measuring the level of
Aβ1–42 in the ISF obtained by microdialysis after 9 h of the0
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Figure 3 Reduction of Aβ levels in culture medium by NEP2-ex
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As shown in Fig. 6, the administration of iPS-ML-A/NEP2
resulted in decreased Aβ1–42 concentrations in the ISF by
more than 40% as compared with the basal level. The level of
Aβ1–42 in ISF of the mice treated with the iPS-ML-A/NEP2
was significantly lower than that of the mice treated with
non-transfected iPS-ML-A or Ringer's solution. These results
indicate that intracerebral administration of iPS-ML/NEP20
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Figure 4 Inhibition of Aβ oligomer-induced neuronal cell death by NEP2-expressing iPS-ML in vitro. A. SH-SY5Y neuroblastoma cells
were cultured (1 × 104 cells/100 μL/well in 96-well plates) in the presence of the indicated concentrations of Aβ oligomers (AβO).
After 48 h, the number of live cells was analyzed by MTS assay. Data are presented as relative number of cells where the value for
culture of the cells without AβO was defined as 100%, and the mean value + standard error for triplicate cultures are shown. (n = 3,
*P b 0.001). B. Culture supernatants of iPS-ML-A and NEP2-expressing iPS-ML-A (iPS-ML-A/NEP2) were prepared as in Fig. 3B. SH-SY5Y
neuroblastoma cells were cultured (1 × 104 cells/100 μL/well in 96-well plates) in the presence of Aβ (10 μM), and the prepared
iPS-ML culture supernatants were added with or without phosphoramidon (10 μM). After 48 h, the number of live SH-SY5Y cells was
analyzed by MTS assay. Data are presented as relative number of cells where the number in the culture in the absence of Aβ was
defined as 100%, and means + standard error for triplicate cultures are shown. (n = 3, *P b 0.005, **P b 0.001). C. Culture
supernatant of monocyte-derived macrophages (CD14+MP), iPS cell derived without proliferating capacity (iPS-MC), iPS-ML-B, or
NEP2-expressing iPS-ML-B (iPS-ML-B/NEP2) was added to SH-SY5Y cells in the presence of Aβ (10 μM). After 48 h, the number of live
SH-SY5Y cells was analyzed by MTS assay. Data are presented as relative number of cells where the number in the culture in the
absence of Aβ was defined as 100%, and means + standard error for triplicate cultures are shown. (n = 3, *P b 0.05, **P b 0.01,
***P b 0.001).
449Aβ degradation iPS-ML expressing NEP2reduced the concentration of Aβ1–42 in the ISF by
degradation of Aβ1–42 by transgene-derived NEP2.Discussion
Microglia are resident immune cells in the CNS that regulate
innate immunity and participate in adaptive immune
response (Hanisch and Kettenmann, 2007). However, the
roles of microglia in AD pathology are still under debate.
While there is significant evidence that microglial activation
initiates and advances AD pathology, some aspects ofmicroglia function are proposed to be beneficial because
microglia are able to reduce Aβ deposition by phagocytosis
(Gentleman, 2013). In animal models of AD, it has been
reported that deficient microglial phagocytic activity accel-
erates pathology progression (El Khoury et al., 2007;
Hickman et al., 2008), whereas exogenous transplantation
of microglia enabled the clearance of Aβ depositions (Takata
et al., 2007). Results from clinical trials of Aβ peptide
vaccination have suggested microglial phagocytic clearance
of Aβ from the cortex (Zotova et al., 2011).
In mouse models of AD, bone marrow-derived cells have
been shown to reduce the Aβ burden (Lee et al., 2010).
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Figure 6 Degradation of Aβ in brain interstitial fluid of 5XFAD
mice by intrahippocampally administrated NEP2-expressing
iPS-ML. Microdialysis probes were inserted into the hippocampuses
of 5XFAD/scid mice to sample the soluble Aβ in the brain
interstitial fluid (ISF). Ringer's solution as vehicle control (Control),
non-transfected iPS-ML-A, or NEP2-expressing iPS-ML-A (iPS-ML-A/
NEP2) were injected into the right hippocampus via the microin-
jection tubes. Concentrations of Aβ1–42 in dialysis samples
obtained 9 h after the administration of iPS-ML were determined
by ELISA. For each mouse, the Aβ1–42 concentration was
normalized to the basal level, which was the mean Aβ1–42
concentration over the 2 h preceding iPS-ML administration. Data
are presented as mean normalized value + standard error of
experimental groups (n = 4, *P b 0.05, **P b 0.01).
450 K. Takamatsu et al.Furthermore, several groups have recently reported that
bone marrow-derived cells are able to differentiate into
functional microglia (BMDM) and the therapeutic effect of
BMDM in Aβ clearance is also suggested (Magga et al., 2012).
Therefore, bone marrow cells may be an appropriate source
of microglial progenitors for clinical application. Neverthe-
less, the repetitive administration requires a large quantity
of cells. Therefore, to develop a cell-based therapy, it is
necessary to resolve the issue of cell source. We have
previously established a method to generate a large quantity
of macrophage-like myeloid cells (Haruta et al., 2013; Koba
et al., 2013; Senju et al., 2011). Cell-based therapy with
iPS-ML may be one of the promising candidates for future
therapeutic treatments.
Lentiviral modification of hematopoietic stem cells
provided clinical benefits in an X-linked adrenoleukodystro-
phy (Cartier et al., 2009). iPS-ML could also be modified by
the lentivirus vector to produce long-term transgene
expression without compromising cell proliferation or func-
tion. We generated iPS-MC expressing a Fc-receptor-fused
form of the Aβ-specific single chain antibody (scFv).
Phagocytosis of Aβ-coated microbeads by iPS-MC was
significantly enhanced by the expression of the anti-Aβ
scFv (Senju et al., 2011). Recent studies revealed that
soluble oligomeric Aβ (AβO) is the most neurotoxic Aβ
species (Lambert et al., 1998; Walsh et al., 2002; Zahs and
Ashe, 2013). Therefore, in the current study, we examined
whether iPS-ML could reduce the level of AβO in the cultureA
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Figure 5 Intrahippocampal injection of iPS-ML into 5XFAD/scid mice. iPS-ML-A labeled with PKH26 or GFP-expressing iPS-ML-B
were injected into the hippocampus of 5XFAD/SCID mice. After 24 h, mice were sacrificed and the brain tissue was removed.
A. Frozen sections of 20-μm thickness were made and stained with Congo red. B. A merged images with blue fluorescence (DAPI)
indicating cell nucleus and red fluorescence indicating PKH26-stained iPS-ML-A are shown. C. Merged images with blue fluorescence
(DAPI) indicating cell nucleus and green-white fluorescence indicating GFP-expressing iPS-ML-B are shown. The square region in the
upper image is magnified in the lower image.
451Aβ degradation iPS-ML expressing NEP2medium (Fig. 3A). Contrary to our expectation, expression of
anti-Aβ scFv in iPS-ML did not enhance the clearance of
soluble Aβ in the culture medium. On the other hand, forced
expression of a protease with AβO-degrading activity
enhanced the reduction of AβO in the culture medium by
iPS-ML. We observed that the iPS-ML highly expressing NEP2
(iPS-ML-A/NEP2), a secretable protease with Aβ-degrading
activity, efficiently reduced AβO (Fig. 3B). In addition,
culture supernatant of iPS-ML with or without expression of
NEP2 inhibited the AβO-induced death of neuronal cells in
vitro (Figs. 4B, C). Culture supernatant of iPS-MC, iPS
cell-derived myeloid cells without proliferating capacity,
also exhibited such effect (Fig. 4C). On the other hand,
human peripheral blood monocyte-derived macrophages
(CD14+ MP) did not exhibit such effect (Fig. 4C).
Microglia act as a source of neurotrophic factors andmitigate
neurodegeneration. Microglia-derived neurotrophic factors,
such as the brain-derived neurotrophic factor (BDNF), exert
well-documented neuroprotective functions (Nagahara et al.,
2009). The protection of SH-SY5 cells from AβO-induced death
by the culture supernatant of the non-transfected iPS-ML
(Figs. 4B, C) may have been mediated by some neurotrophic
agents produced by the iPS-ML. Someof soluble factors secreted
by CD14+MP, iPS-MC, iPS-ML, or NEP2-expressing iPS-ML were
examined by bead array system and the results are shown in
Supplementary Fig. 3.
To develop an effective cell-based therapy against neuro-
degenerative disorders of the CNS, efficient recruitment of the
cells into the CNS is essential. Previous findings suggest that
particular bone marrow derived cells are able to cross the
blood–brain barrier (Lebson et al., 2010; Simard and Rivest,
2004). To evaluate the migration of the iPS-ML into the CNS,
we examined the effect of intravenous, intraperitoneal, and
intracerebroventricular injection of iPS-ML into 5XFAD mice.
To our disappointment, the iPS-ML injected via these routes
did not efficiently infiltrate into brain parenchyma and failed
to reduce the amyloid burden. A possible reason of the failure
to efficiently migrate in brain tissue may be the lack of CC
chemokine receptor-2 (CCR2) expression in the iPS-ML (data
not shown). To analyze the in vivo effect of iPS-ML/NEP2, we
directly administered iPS-ML into the brain. To this end, we
stereotaxically inserted microinjection tubes into the hippo-
campus of 5XFAD mice and transplanted iPS-ML through this
tube. The hippocampus plays a major role in cognitive
dysfunction of AD, and the 5XFAD hippocampus is one of the
regions of the brain where Aβ plaques accumulate. iPS-ML
transplanted by this procedure migrated to the brain paren-
chyma adjacent to the area of the tube insertion (Figs. 5B, C).
In vivo, transplantation of iPS-ML/NEP2 into the hippo-
campus of 3–4-month old 5XFAD/scid mice significantly
diminished the levels of soluble Aβ1–42 in the brain ISF
compared to the control Ringer's solution injection (Fig. 6).
The reduction of Aβ was not significant when non-modified
iPS-ML were transplanted. Therefore, the reduction of Aβ
was caused by the secretion of NEP2 from the iPS-ML, but
not phagocytosis of Aβ by the iPS-ML. Our intrahippocampus
transplantation of iPS-ML demonstrated short-term and focal
remote effects of the IPS-ML; only where the cells were
transplanted. Furthermore we could not examine the
therapeutic effect of cognitive function, because the mice
were weakened by probe implantation. Future studies will
be aimed at exploring whether iPS-ML are effective inpreventing cognitive decline and neuronal damage in other
AD models. In addition, to develop this technique as a
therapy for AD, delivery of iPS-ML into the brain by systemic
administration is necessary.
To examine the chromosomal alteration of iPS-ML, iPS-ML
cultured for 6 weeks after the introduction of proliferating
factors were subjected to karyotype analysis. As shown in
Supplemental Fig. S1, some karyotype abnormalities were
detected in this analysis. For application of iPS-ML to clinical
cellular therapy, we should resolve the issue of genetic
instability of iPS-ML. To generate iPS-ML, our current
method uses cMYC, BMI1 plus MDM2 to induce proliferation
of iPS-MC. Among the introduced factors, MDM2 is involved
in degradation of p53 protein as the E3 ubiquitin ligase
(Haupt et al., 1997; Honda et al., 1997; Kubbutat et al.,
1997). Forced expression of MDM2 in iPS-ML may cause
complete loss of p53 function and result in the genetic
instability of iPS-ML. Although co-introduction of MDM2
enhanced the proliferation rate of iPS-ML, this factor is not
absolutely necessary for the establishment of iPS-ML, as
previously reported (Haruta et al., 2013; Koba et al., 2013).
Omission of MDM2 in the generation of iPS-ML may be one
way to improve the genetic stability of iPS-ML.
The risk of tumor occurrence is one of most serious issues
to be resolved before the clinical application. We currently
use a lentivirus vector to introduce proliferation factors to
generate iPS-ML, and administration of such iPS-ML to the
patients may cause malignancy. Thus, for the clinical
application of iPS-ML-based cellular therapy, a removable
vector system should be used to generate iPS-ML.
In addition to AD, many intractable diseases are caused
by the accumulation of misfolded proteins. Furthermore,
the potential of iPS-ML may involve genetic modification to
produce proteolytic enzymes that degrade other deleterious
misfolded proteins or prion. We are planning future studies
to evaluate the potential of iPS-ML as cell-based therapeu-
tics for neurodegenerative diseases other than AD and
various types of amyloidosis.
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